Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Journal of Proteomics

Volumn 136, Issue , 2016, Pages 89-98

  Harshman, Sean W ^a,b   Canella, Alessandro ^b   Ciarlariello, Paul D ^b   Agarwal, Kitty ^a   Branson, Owen E ^a   Rocci, Alberto ^c   Cordero, Hector ^a   Phelps, Mitch A ^a   Hade, Erinn M ^a   Dubovsky, Jason A ^a   Palumbo, Antonio ^d   Rosko, Ashley ^a   Byrd, John C ^a   Hofmeister, Craig C ^a   Benson, Don M ^a   Paulaitis, Michael E ^a,e   Freitas, Michael A ^a,b   Pichiorri, Flavia ^a,f  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e The Ohio State University   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cd44; Extracellular vesicles; Label free relative quantitation; Multiple myeloma; Shotgun proteomics

Indexed keywords

BETA 2 MICROGLOBULIN; BINDING PROTEIN; BIOLOGICAL MARKER; CORTICOSTEROID; HERMES ANTIGEN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; CD44 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; EXOSOME; HUMAN; HUMAN CELL; IMMUNE EVASION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR CELL LINE;

ANTIGENS, CD44; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROTEOMICS; SURVIVAL RATE;

EID: 84959266374     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.12.016     Document Type: Article

References (56)

1. American Cancer Society Cancer Facts & Figures 2011, 1-68. (http://www.cancer.org/acs/groups/content/epidemiologysurveilance/documents/document/acspc-031941.pdf).
2. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2002, 2:175-187.
3. Reagan M.R., Ghobrial I.M. Multiple myeloma-mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 2012, 18:342-349.
4. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.-T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 2013, 123:1542-1555.
5. Vacca A., Ribatti D., Roccaro A.M., Frigeri A., Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin. Oncol. 2001, 28:543-550.
6. Mahindra A., Hideshima T., Anderson K.C. Multiple myeloma: biology of the disease. Blood Rev. 2010, 24:S5-S11.
7. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
8. Wang J., Hendrix A., Hernot S., Lemaire M., De Bruyne E., Van Valckenborgh E., et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 2014, 124:555-566.
9. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta Gen. Subj. 2012, 1820:940-948.
10. Denzer K., Kleijmeer M.J., Heijnen H.F., Stoorvogel W., Geuze H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. 2000, 113:3365-3374.
11. Théry C., Boussac M., Véron P., Ricciardi-Castagnoli P., Raposo G., Garin J., et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001, 166:7309-7318.
12. Wubbolts R., Leckie R.S., Veenhuizen P.T.M., Schwarzmann G., Möbius W., Hoernschemeyer J., et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J. Biol. Chem. 2003, 278:10963-10972.
13. Harshman S.W., Canella A., Ciarlariello P.D., Rocci A., Agarwal K., Smith E.M., et al. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics 2013, 13:3013-3029.
14. Edwards C.M., Lwin S.T., Fowler J.A., Oyajobi B.O., Zhuang J., Bates A.L., et al. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am. J. Hematol. 2009, 84:268-272.
15. Pokharel D., Padula M.P., Lu J.F., Tacchi J.L., Luk F., Djordjevic S.P., et al. Proteome analysis of multidrug-resistant, breast cancer-derived microparticles. J. Extracell. Vesicles 2014, 3:24384.
16. Choi D.-Y., You S., Jung J.H., Lee J.C., Rho J.K., Lee K.Y., et al. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics 2014, 14:1845-1856.
17. Ma X., Chen Z., Hua D., He D., Wang L., Zhang P., et al. Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:6389-6394.
18. Ahrens T., Assmann V., Fieber C., Termeer C.C., Herrlich P., Hofmann M., et al. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Investig. Dermatol. 2001, 116:93-101.
19. Ahrens T., Sleeman J.P., Schempp C.M., Howells N., Hofmann M., Ponta H., et al. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 2001, 20:3399-3408.
20. Naor D., Sionov R.V., Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 1997, 71:241-319.
21. Buschow S.I., van Balkom B.W.M., Aalberts M., Heck A.J.R., Wauben M., Stoorvogel W. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol. Cell Biol. 2010, 88:851-856.
22. Welton J.L., Khanna S., Giles P.J., Brennan P., Brewis I.A., Staffurth J., et al. Proteomics analysis of bladder cancer exosomes. Mol. Cell. Proteomics 2010, 9:1324-1338.
23. Choi D.-S., Park J.O., Jang S.C., Yoon Y.J., Jung J.W., Choi D.-Y., et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics 2011, 11:2745-2751.
24. Mathivanan S., Lim J.W.E., Tauro B.J., Ji H., Moritz R.L., Simpson R.J. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteomics 2010, 9:197-208.
25. Gonzalez-Begne M., Lu B., Han X., Hagen F.K., Hand A.R., Melvin J.E., et al. Proteomic analysis of human parotid gland exosomes by Multidimensional Protein Identification Technology (MudPIT). J. Proteome Res. 2009, 8:1304-1314.
26. Ohwada C., Nakaseko C., Koizumi M., Takeuchi M., Ozawa S., Naito M., et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur. J. Haematol. 2008, 80:245-250.
27. Bjorklund C.C., Baladandayuthapani V., Lin H.Y., Jones R.J., Kuiatse I., Wang H., et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014, 28:373-383.
28. Théry C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, (Chapter 3, Unit 3.22).
29. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003, 121:749-757.
30. Rajkumar S.V. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2012, 87:78-88.
31. Shapiro J.P., Biswas S., Merchant A.S., Satoskar A., Taslim C., Lin S., et al. A quantitative proteomic workflow for characterization of frozen clinical biopsies: laser capture microdissection coupled with label-free mass spectrometry. J. Proteome 2012, 77:433-440.
32. Xu H., Freitas M.A. A mass accuracy sensitive probability based scoring algorithm for database searching of tandem mass spectrometry data. BMC Bioinformatics 2007, 8:133.
33. Xu H., Yang L., Freitas M.A. A robust linear regression based algorithm for automated evaluation of peptide identifications from shotgun proteomics by use of reversed-phase liquid chromatography retention time. BMC Bioinformatics 2008, 9:347.
34. Xu H., Zhang L., Freitas M.A. Identification and characterization of disulfide bonds in proteins and peptides from tandem MS data by use of the MassMatrix MS/MS search engine. J. Proteome Res. 2008, 7:138-144.
35. Xu H., Freitas M.A. Monte Carlo simulation-based algorithms for analysis of shotgun proteomic data. J. Proteome Res. 2008, 7:2605-2615.
36. Zhang B., Chambers M.C., Tabb D.L. Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. J. Proteome Res. 2007, 6:3549-3557.
37. Palumbo A. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 2010, 28:5101-5109.
38. Ross F.M. The T(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. haematologica 2010, 95:1221-1225.
39. Munshi N.C. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 4694-4700.
40. Yi E.C., Lee H., Aebersold R., Goodlett D.R. A microcapillary trap cartridge-microcapillary high-performance liquid chromatography electrospray ionization emitter device capable of peptide tandem mass spectrometry at the attomole level on an ion trap mass spectrometer with automated routine operation. Rapid Commun. Mass Spectrom. 2003, 17:2093-2098.
41. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76:4193-4201.
42. Colinge J., Chiappe D., Lagache S., Moniatte M., Bougueleret L. Differential proteomics via probabilistic peptide identification scores. Anal. Chem. 2005, 77:596-606.
43. Hulsen T., de Vlieg J., Alkema W. BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 2008, 9:488.
44. Thomas P.D., Kejariwal A., Campbell M.J., Mi H., Diemer K., Guo N., et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 2003, 31:334-341.
45. Mi H., Dong Q., Muruganujan A., Gaudet P., Lewis S., Thomas P.D. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res. 2010, 38:D204-D210.
46. Vraetz T., Ittel T.H., van Mackelenbergh M.G., Heinrich P.C., Sieberth H.G., Graeve L. Regulation of β2-microglobulin expression in different human cell lines by proinflammatory cytokines. Nephrol. Dial. Transplant. 1999, 14:2137-2143.
47. Tanaka Y., Kamohara H., Kinoshita K., Kurashige J., Ishimoto T., Iwatsuki M., et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 2013, 119:1159-1167.
48. Yang X., Iyer A.K., Singh A., Milane L., Choy E., Hornicek F.J., et al. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm. Res. 2015, 32:2097-2109.
49. Yoon C., Park D.J., Schmidt B., Thomas N.J., Lee H.-J., Kim T.S., et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin. Cancer Res. 2014, 20:3974-3988.
50. Vincent T., Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004, 18:967-975.
51. Hertweck M.K., Erdfelder F., Kreuzer K.-A. CD44 in hematological neoplasias. Ann. Hematol. 2011, 90:493-508.
52. Stauder R., Van Driel M., Schwarzler C., Thaler J., Lokhorst H.M., Kreuser E.D., et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996, 88:3101-3108.
53. Kumar S.K., Uno H., Jacobus S.J., Van Wier S.A., Ahmann G.J., Henderson K.J., et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011, 118:4359-4362.
54. Weinstock M., Aljawai Y., Morgan E.A., Laubach J., Gannon M., Roccaro A.M., et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br. J. Haematol. 2015, 169:851-858.
55. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
56. Kahlert C., Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. 2013, 91:431-437.